Sir David Jack: an Extraordinary Drug Discoverer and Developer

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2012 Sep 22

PMID 22994263

Citations 1

Authors

Clive Page

Patrick Humphrey

Affiliations

Soon will be listed here.

Citing Articles

It is time to end our love affair with short-acting β-agonists in asthma.

Crooks M, Faruqi S ERJ Open Res. 2022; 8(4).

PMID: 36267894 PMC: 9574554. DOI: 10.1183/23120541.00353-2022.

References

Lemanske Jr R, Busse W . The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?. J Allergy Clin Immunol. 2010; 126(3):449-52. DOI: 10.1016/j.jaci.2010.05.039. View

Brittain R, Tyers M . The pharmacology of AH8165: a rapid-acting, short-lasting, competitive neuromuscular blocking drug. Br J Anaesth. 1973; 45(8):837-43. DOI: 10.1093/bja/45.8.837. View

Coleman R, Smith W, Narumiya S . International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994; 46(2):205-29. View

Humphrey P . How it started. Cephalalgia. 2001; 21 Suppl 1:2-5. DOI: 10.1046/0333102401021s0102. View

Coleman R, Kennedy I . Contractile and relaxant actions of prostaglandins on guinea-pig isolated trachea. Br J Pharmacol. 1980; 68(3):533-9. PMC: 2044219. DOI: 10.1111/j.1476-5381.1980.tb14569.x. View

Cazzola M, Page C, Calzetta L, Matera M . Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012; 64(3):450-504. DOI: 10.1124/pr.111.004580. View

Humphrey P . The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008; 48(5):685-7. DOI: 10.1111/j.1526-4610.2008.01097.x. View

Page C . One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet. 1991; 337(8743):717-20. DOI: 10.1016/0140-6736(91)90289-2. View

Tyers M, Bunce K, Humphrey P . Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol. 1989; 25 Suppl 1:S15-9. View

10.

Humphrey P, Bountra C, Clayton N, Kozlowski K . Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1999; 13 Suppl 2:31-8. View

11.

Hicks G, Coldwell J, Schindler M, Ward P, Jenkins D, Lynn P . Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J Physiol. 2002; 544(3):861-9. PMC: 2290619. DOI: 10.1113/jphysiol.2002.025452. View

12.

Boswell-Smith V, Spina D, Oxford A, Comer M, Seeds E, Page C . The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565.... J Pharmacol Exp Ther. 2006; 318(2):840-8. DOI: 10.1124/jpet.105.099192. View

13.

ULLMAN A, SVEDMYR N . Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988; 43(9):674-8. PMC: 461454. DOI: 10.1136/thx.43.9.674. View

14.

Kennedy I, Coleman R, Humphrey P, Lumley P . Studies on the characterization of prostanoid receptors. Adv Prostaglandin Thromboxane Leukot Res. 1983; 11:327-32. View

15.

Humphrey P, Hallet P, Hornby E, Wallis C, Collington E, Lumley P . Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. Circulation. 1990; 81(1 Suppl):I42-52; discussion I59-60. View

16.

Lumley P, White B, Humphrey P . GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol. 1989; 97(3):783-94. PMC: 1854582. DOI: 10.1111/j.1476-5381.1989.tb12017.x. View

17.

Woodings E, Dixon G, Harrison C, Carey P, Richards D . Ranitidine--a new H2-receptor antagonist. Gut. 1980; 21(3):187-91. PMC: 1420359. DOI: 10.1136/gut.21.3.187. View

18.

Costall B, Naylor R, Tyers M . The psychopharmacology of 5-HT3 receptors. Pharmacol Ther. 1990; 47(2):181-202. DOI: 10.1016/0163-7258(90)90086-h. View

19.

Brittain R, Levy G . A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. Br J Clin Pharmacol. 1976; 3(4 Suppl 3):681-4. View

20.

Butler A, Hill J, Ireland S, Jordan C, Tyers M . Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol. 1988; 94(2):397-412. PMC: 1854010. DOI: 10.1111/j.1476-5381.1988.tb11542.x. View